Luteinizing hormone compromises the in vivo anti-tumor effect of cisplatin on human epithelial ovarian cancer cells

Huang,Yan; Zhou,Yuqi; Xia,Lingfang; Tang,Jia; Wen,Hao; Zhang,Meiqin

doi:10.3892/ol.2017.7655

Luteinizing hormone compromises the in vivo anti-tumor effect of cisplatin on human epithelial ovarian cancer cells

Authors:
- Yan Huang
- Yuqi Zhou
- Lingfang Xia
- Jia Tang
- Hao Wen
- Meiqin Zhang
View Affiliations

Affiliations: Department of Gynecologic Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China
Published online on: December 19, 2017 https://doi.org/10.3892/ol.2017.7655
Pages: 3141-3146

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Platinum-based chemotherapy is the most common therapeutic regimen used to treat patients with ovarian cancer. However, the emergence of drug resistance to platinum compromises the clinical success of this treatment. Epithelial ovarian cancer is usually accompanied by an increased level of luteinizing hormone (LH). Therefore, the effect of LH on platinum resistance requires further investigation. In the current study, the effect of cisplatin and/or LH on platinum resistance was examined using the SKOV3ip1 and HeyA8 models. Following therapy, tumors were examined for proliferation (ki67) and apoptosis (cleaved caspase‑3). Cisplatin alone and in combination with LH significantly inhibited tumor growth in SKOV3ip1‑ and HeyA8‑implanted mice. Treatment with LH alone had minimal effect in the models. However, treatment with cisplatin combined with LH was less effective than treatment with cisplatin alone. Additionally, ki67 counts were significantly increased and cleaved caspase‑3 counts were significantly reduced in mice treated with cisplatin combined with LH compared with mice treated with cisplatin alone. Such results indicate that LH weakens the anti‑tumor effect of cisplatin in vivo and that LH may contribute to the development of drug resistance to cisplatin in ovarian cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Stadel BV: Letter: The etiology and prevention of ovarian cancer. Am J Obstet Gynecol. 123:772–774. 1975. View Article : Google Scholar : PubMed/NCBI
3	Mertens-Walker I, Baxter RC and Marsh DJ: Gonadotropin signalling in epithelial ovarian cancer. Cancer Lett. 324:152–159. 2012. View Article : Google Scholar : PubMed/NCBI
4	Venn A, Watson L, Bruinsma F, Giles G and Healy D: Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet. 354:1586–1590. 1999. View Article : Google Scholar : PubMed/NCBI
5	Brekelmans CT: Risk factors and risk reduction of breast and ovarian cancer. Curr Opin Obstet Gynecol. 15:63–68. 2003. View Article : Google Scholar : PubMed/NCBI
6	Holschneider CH and Berek JS: Ovarian cancer: Epidemiology, biology, and prognostic factors. Semin Surg Oncol. 19:3–10. 2000. View Article : Google Scholar : PubMed/NCBI
7	Tavani A, Ricci E, La Vecchia C, Surace M, Benzi G, Parazzini F and Franceschi S: Influence of menstrual and reproductive factors on ovarian cancer risk in women with and without family history of breast or ovarian cancer. Int J Epidemiol. 29:799–802. 2000. View Article : Google Scholar : PubMed/NCBI
8	Daly M and Obrams GI: Epidemiology and risk assessment for ovarian cancer. Semin Oncol. 25:255–264. 1998.PubMed/NCBI
9	Gnagy S, Ming EE, Devesa SS, Hartge P and Whittemore AS: Declining ovarian cancer rates in U.S. women in relation to parity and oral contraceptive use. Epidemiology. 11:102–105. 2000. View Article : Google Scholar : PubMed/NCBI
10	Zheng W, Lu JJ, Luo F, Zheng Y, Feng Yj, Felix JC, Lauchlan SC and Pike MC: Ovarian epithelial tumor growth promotion by follicle-stimulating hormone and inhibition of the effect by luteinizing hormone. Gynecol Oncol. 76:80–88. 2000. View Article : Google Scholar : PubMed/NCBI
11	Kurbacher CM, Jäger W, Kurbacher JA, Bittl A, Wildt L and Lang N: Influence of human luteinizing hormone on cell growth and CA 125 secretion of primary epithelial ovarian carcinomas in vitro. Tumour Biol. 16:374–384. 1995. View Article : Google Scholar : PubMed/NCBI
12	Kuroda H, Mandai M, Konishi I, Yura Y, Tsuruta Y, Hamid AA, Nanbu K, Matsushita K and Mori T: Human chorionic gonadotropin (hCG) inhibits cisplatin-induced apoptosis in ovarian cancer cells: Possible role of up-regulation of insulin-like growth factor-1 by hCG. Int J Cancer. 76:571–578. 1998. View Article : Google Scholar : PubMed/NCBI
13	Tashiro H, Miyazaki K, Okamura H, Iwai A and Fukumoto M: c-myc over-expression in human primary ovarian tumours: Its relevance to tumour progression. Int J Cancer. 50:828–833. 1992. View Article : Google Scholar : PubMed/NCBI
14	Tourgeman DE, Lu JJ, Boostanfar R, Amezcua C, Felix JC and Paulson RJ: Human chorionic gonadotropin suppresses ovarian epithelial neoplastic cell proliferation in vitro. Fertil Steril. 78:1096–1099. 2002. View Article : Google Scholar : PubMed/NCBI
15	Choi JH, Choi KC, Auersperg N and Leung PC: Gonadotropins activate proteolysis and increase invasion through protein kinase A and phosphatidylinositol 3-kinase pathways in human epithelial ovarian cancer cells. Cancer Res. 66:3912–3920. 2006. View Article : Google Scholar : PubMed/NCBI
16	Tilly JL, Tilly KI, Kenton ML and Johnson AL: Expression of members of the bcl-2 gene family in the immature rat ovary: Equine chorionic gonadotropin-mediated inhibition of granulosa cell apoptosis is associated with decreased bax and constitutive bcl-2 and bcl-xlong messenger ribonucleic acid levels. Endocrinology. 136:232–241. 1995. View Article : Google Scholar : PubMed/NCBI
17	Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M and Kroemer G: Molecular mechanisms of cisplatin resistance. Oncogene. 31:1869–1883. 2012. View Article : Google Scholar : PubMed/NCBI
18	Xia L, Wen H, Han X, Tang J and Huang Y: Luteinizing hormone inhibits cisplatin-induced apoptosis in human epithelial ovarian cancer cells. Oncol Lett. 11:1943–1947. 2016. View Article : Google Scholar : PubMed/NCBI
19	Lu C, Shahzad MM, Moreno-Smith M, Lin YG, Jennings NB, Alle JK, Landen CN, Mangala LS, Armaiz-Pena GN, Schmandt R, et al: Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther. 9:176–182. 2010. View Article : Google Scholar : PubMed/NCBI
20	Guide for the Care and Use of Laboratory Animals, . National Research Council (US) Committee for the update of the guide for the care and use of laboratory animals. 8th. Washington (DC): National Academies Press (US); 2011
21	Huang Y, Jin H, Liu Y, Zhou J, Ding J, Cheng KW, Yu Y and Feng Y: FSH inhibits ovarian cancer cell apoptosis by up-regulating survivin and down-regulating PDCD6 and DR5. Endocr Relat Cancer. 18:13–26. 2010. View Article : Google Scholar : PubMed/NCBI
22	Garofalo A, Naumova E, Manenti L, Ghilardi C, Ghisleni G, Caniatti M, Colombo T, Cherrington JM, Scanziani E, Nicoletti MI and Giavazzi R: The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res. 9:3476–3485. 2003.PubMed/NCBI
23	Scholzen T and Gerdes J: The Ki-67 protein: From the known and the unknown. J Cell Physiol. 182:311–322. 2000. View Article : Google Scholar : PubMed/NCBI
24	Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell. 78:539–542. 1994. View Article : Google Scholar : PubMed/NCBI
25	Huang Y, Hua K, Zhou X, Jin H, Chen X, Lu X, Yu Y, Zha X and Feng Y: Activation of the PI3K/AKT pathway mediates FSH-stimulated VEGF expression in ovarian serous cystadenocarcinoma. Cell Res. 18:780–791. 2008. View Article : Google Scholar : PubMed/NCBI
26	Zhang Z, Liao H, Chen X, Zheng Y, Liu Y, Tao X, Gu C, Dong L, Duan T, Yang Y, et al: Luteinizing hormone upregulates survivin and inhibits apoptosis in ovarian epithelial tumors. Eur J Obstet Gynecol Reprod Biol. 155:69–74. 2011. View Article : Google Scholar : PubMed/NCBI
27	Xia L, Wen H, Han X, Tang J and Huang Y: Luteinizing hormone inhibits cisplatin-induced apoptosis in human epithelial ovarian cancer cells. Oncol Lett. 11:1943–1947. 2016. View Article : Google Scholar : PubMed/NCBI
28	Liao H, Zhou Q, Gu Y, Duan T and Feng Y: Luteinizing hormone facilitates angiogenesis in ovarian epithelial tumor cells and metformin inhibits the effect through the mTOR signaling pathway. Oncol Rep. 27:1873–1878. 2012.PubMed/NCBI
29	Rzepka-Górska I, Chudecka-Głaz A and Kosmowska B: FSH and LH serum/tumor fluid ratios and malignant tumors of the ovary. Endocr Relat Cancer. 11:315–321. 2004. View Article : Google Scholar : PubMed/NCBI
30	Kim JH, Jeong SJ, Kim B, Yun SM, Choi DY and Kim SH: Melatonin synergistically enhances cisplatin-induced apoptosis via the dephosphorylation of ERK/p90 ribosomal S6 kinase/heat shock protein 27 in SK-OV-3 cells. J Pineal Res. 52:244–252. 2012. View Article : Google Scholar : PubMed/NCBI
31	Mabuchi S, Altomare DA, Cheung M, Zhang L, Poulikakos PI, Hensley HH, Schilder RJ, Ozols RF and Testa JR: RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model. Clin Cancer Res. 13:4261–4270. 2007. View Article : Google Scholar : PubMed/NCBI
32	Tan O and Bukulmez O: Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists. Curr Opin Obstet Gynecol. 23:238–244. 2011. View Article : Google Scholar : PubMed/NCBI